KRAS and pancreatic neoplasm: The presence of a KRAS mutation is seen in 30% of premalignant lesions [3] and in up to 90% of pancreatic cancer tumor specimens [4], suggesting that the KRAS mutation is the predominant known feature of pancreatic cancer molecular pathogenesis.